NCT02937675 - A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

November 12, 2018

Study Completion Date

April 4, 2019

Conditions

Lymphoma

Interventions

DRUG

Tomivosertib (eFT-508)

eFT508

Trial Locations (10)

University of Rochester, Rochester

West Virginia University, Morgantown

Florida Cancer Specialist, Sarasota

Gabrail Cancer Center Research, Canton

Karmanos Cancer Institute, Detroit

Henry Ford Hospital, Detroit

Mayo Clinic, Rochester

Baylor Scott & White Research Institute, Dallas

Samuel Oschin comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles

Seattle Cancer Care Alliance, Seattle